+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type, By Drug Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

  • ID: 5410181
  • Report
  • August 2021
  • Region: Global
  • 117 Pages
  • TechSci Research
UP TO OFF
until Dec 31st 2021
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is Expected to Reach USD 14689.31 Million in 2026.

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Eli Lilly and Company.
  • F. Hoffmann-La Roche Ltd
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% during the forecast period, owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin’s lymphomas (NHL). Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.

Non-Hodgkin’s lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body’s immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them. In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas. B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.

Regionally, North America dominated the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market in 2020 and is further expected to hold its dominance during the forecast period. High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market. However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.

Major companies operating in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc., among others. The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin’s lymphoma therapeutics market. Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market from 2016 to 2020.
  • To estimate and forecast the market size of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market based on type of therapy, cell type, drug type, distribution channel, company and regional distribution from 2021 to 2026 and growth rate until 2026.
  • To identify drivers and challenges for the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.
  • To identify and analyze the profile of leading players operating in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies which could not be identified due to the limitations of secondary research.

The publisher calculated the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market size by using a bottom-up approach, where data for various end-user industries and its application across various product types were recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used.

Key Target Audience:

  • Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to Non-Hodgkin Lymphoma (NHL) therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as Non-Hodgkin Lymphoma (NHL) Therapeutics manufacturing companies, end-users etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Stem Cell Transplant
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:

  • B-cell Lymphomas
  • T-cell Lymphomas

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:

  • Revlimid
  • Rituxan
  • Keytruda
  • Imbruvica
  • Opdivo
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.

Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Eli Lilly and Company.
  • F. Hoffmann-La Roche Ltd
1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market

4. Executive Summary

5. Voice of Customer
5.1. Brand Awareness
5.2. Unmet Needs & Challenges
5.3. Factors Influencing Drug Purchase

6. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
6.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
6.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
6.2.5. By Company (2020)
6.2.6. By Region
6.3. Product Market Map

7. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Cell Type
7.2.3. By Drug Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Therapy
7.3.1.2.2. By Cell Type
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Distribution Channel
7.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Therapy
7.3.2.2.2. By Cell Type
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Distribution Channel
7.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type of Therapy
7.3.3.2.2. By Cell Type
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Distribution Channel

8. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Therapy
8.2.2. By Cell Type
8.2.3. By Drug Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Therapy
8.3.1.2.2. By Cell Type
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Distribution Channel
8.3.2. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Therapy
8.3.2.2.2. By Cell Type
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Distribution Channel
8.3.3. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Therapy
8.3.3.2.2. By Cell Type
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Therapy
8.3.4.2.2. By Cell Type
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Therapy
8.3.5.2.2. By Cell Type
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Therapy
9.2.2. By Cell Type
9.2.3. By Drug Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Therapy
9.3.1.2.2. By Cell Type
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Distribution Channel
9.3.2. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Therapy
9.3.2.2.2. By Cell Type
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Distribution Channel
9.3.3. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Therapy
9.3.3.2.2. By Cell Type
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Distribution Channel
9.3.4. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type of Therapy
9.3.4.2.2. By Cell Type
9.3.4.2.3. By Drug Type
9.3.4.2.4. By Distribution Channel
9.3.5. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type of Therapy
9.3.5.2.2. By Cell Type
9.3.5.2.3. By Drug Type
9.3.5.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type of Therapy
10.2.2. By Cell Type
10.2.3. By Drug Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type of Therapy
10.3.1.2.2. By Cell Type
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type of Therapy
10.3.2.2.2. By Cell Type
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type of Therapy
10.3.3.2.2. By Cell Type
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type of Therapy
11.2.2. By Cell Type
11.2.3. By Drug Type
11.2.4. By Distribution Channel
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type of Therapy
11.3.1.2.2. By Cell Type
11.3.1.2.3. By Drug Type
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type of Therapy
11.3.2.2.2. By Cell Type
11.3.2.2.3. By Drug Type
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type of Therapy
11.3.3.2.2. By Cell Type
11.3.3.2.3. By Drug Type
11.3.3.2.4. By Distribution Channel

12. Market Dynamics
12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Clinical Trial Analysis

15. Competitive Landscape
15.1. Competition Outlook
15.2. Players Profiled (Leading Companies)
15.2.1. AstraZeneca PLC
15.2.2. Baxter International Inc.
15.2.3. Bayer AG
15.2.4. Novartis AG
15.2.5. Eli Lilly and Company.
15.2.6. Spectrum Pharmaceuticals, Inc.
15.2.7. Teva Pharmaceutical Industries Ltd.
15.2.8. Bristol Myers Squibb Company
15.2.9. GlaxoSmithKline PLC
15.2.10. Janssen Pharmaceuticals, Inc.
15.2.11. F. Hoffmann-La Roche Ltd
15.2.12. Sanofi S.A.
15.2.13. Merck & Co., Inc.
15.2.14. Takeda Pharmaceutical Company Limited
15.2.15. AbbVie Inc.

16. Strategic Recommendations

17. About the Publisher & Disclaimer

List of Figures
Figure 1: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 2: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 3: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 4: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 5: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 6: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Company, 2020
Figure 7: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Region, By Value, 2016-2026F
Figure 8: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Product Market Map, By Value, 2016-2026F
Figure 9: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 10: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 11: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 12: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 13: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 14: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 15: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 16: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 17: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 18: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 19: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 20: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 21: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 22: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 23: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 24: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 25: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 26: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 27: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 28: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 29: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 30: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 31: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 32: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 33: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 34: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 35: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 36: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 37: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 38: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 39: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 40: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 41: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 42: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 43: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 44: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 45: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 46: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 47: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 48: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 49: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 50: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 51: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 52: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 53: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 54: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 55: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 56: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 57: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 58: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 59: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 60: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 61: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 62: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 63: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 64: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 65: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 66: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 67: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 68: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 69: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 70: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 71: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 72: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 73: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 74: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 75: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 76: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 77: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 78: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 79: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 80: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 81: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 82: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 83: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 84: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 85: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 86: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 87: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 88: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 89: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 90: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 91: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 92: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 93: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 94: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 95: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 96: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 97: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 98: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 99: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 100: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 101: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 102: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 103: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 104: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 105: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 106: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 107: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 108: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 109: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 110: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 111: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 112: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 113: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 114: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 115: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 116: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 117: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F
Figure 118: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 119: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 120: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 121: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 122: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 123: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 124: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 125: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 126: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 127: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Figure 128: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F
Figure 129: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F
Figure 130: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F
Figure 131: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F
Figure 132: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Novartis AG
  • Eli Lilly and Company.
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
Note: Product cover images may vary from those shown
Adroll
adroll